glp 1 drug zepbound Eli Lilly's New $299 Month-Long GLP‑1 Injector Shows Why It's Winning the Weight‑Loss Race Study flags need to monitor

Mann, T

Answer : The driving factors of the Australia GLP-1 receptor agonist market are the safety and efficacy of GLP-1 receptor agonists for type 2 diabetes and obesity management is increasing the demand and adoption in the Australian population

Ganamurali et al

Lancet (London, England) 403(10437):16351648 Shah SJ, Sharma K, Borlaug BA, Butler J, Davies M, Kitzman DW, Petrie MC, Verma S, Patel S, Chinnakondepalli KM et al (2024) Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials

[DOI] [PubMed] [Google Scholar] 18.Thomas M.C., Brownlee M., Susztak K., Sharma K., Jandeleit-Dahm K.A.M., Zoungas S., Rossing P., Groop P.-H., Cooper M.E

& Bergman, R